Uncomplicated malaria in pregnancy — DTM&H MCQ

Correct answer: D — An artemisinin-based combination therapy appropriate to local policy

The correct answer is D, an artemisinin-based combination therapy appropriate to local policy. At 24 weeks (second trimester) with uncomplicated, tolerated oral falciparum malaria, UK malaria treatment guidelines recommend an ACT, specifically artemether-lumefantrine, as first-line therapy, reserving quinine-based regimens largely for the first trimester when ACT safety data are more limited. Falciparum malaria in pregnancy carries substantially increased risk of severe disease, miscarriage, stillbirth and low birthweight, so prompt effective treatment matched to local resistance patterns (as in northern Tanzania, an ACT-sensitive area) is essential rather than defaulting to older, less effective regimens. Human pregnancy exposure data have not shown increased miscarriage risk with artemisinin derivatives, supporting their second and third trimester use. Why the other options are wrong: C. Primaquine radical cure after delivery: primaquine targets P. vivax/ovale hypnozoites and gametocytes, is contraindicated in pregnancy due to fetal haemolysis risk from unknown G6PD status, and is entirely irrelevant to treating an acute falciparum blood-stage infection now. A. Chloroquine monotherapy for 3 days: chloroquine has widespread P. falciparum resistance across East Africa including Tanzania, making it ineffective and inappropriate regardless of pregnancy status. B. Doxycycline with quinine for 7 days: doxycycline is contraindicated throughout pregnancy due to risk of fetal teeth discolouration and bone effects, so this combination is unsafe even though quinine itself is used in the first trimester. E. Delay treatment until microscopy is repeated: the diagnosis is already established and delaying treatment in pregnancy risks rapid progression to severe malaria, placental parasitaemia and fetal compromise. Key point: In the second and third trimester of pregnancy, uncomplicated falciparum malaria should be treated with an ACT (artemether-lumefantrine) per local resistance policy, not quinine-based or chloroquine regimens.

Reference: UK malaria treatment guidelines 2016 (Journal of Infection / PHE); UKTIS monograph, Use of Artemisinin and Artemisinin Derivatives in Pregnancy, https://uktis.org/monographs/use-of-artemisinin--artemisinin-derivatives-in-pregnancy/